Alan Keith Boyd
Directeur Général chez Alan Boyd Consultants Ltd.
Profil
Alan Keith Boyd is the founder and CEO of Alan Boyd Consultants Ltd.
founded in 2005.
He is currently a Non-Executive Director at Celentyx Ltd., Spark Therapeutics Ireland Ltd., Transine Therapeutics Ltd., Baxterboyd Ltd., and a Member of The Royal College of Physicians.
Dr. Boyd's former positions include Director-Research & Development at Ark Therapeutics Group Plc from 1999 to 2005, Director-Clinical & Medical Affairs at AstraZeneca Canada, Inc., Medical Director at Clinigen Ltd., Principal at Glaxo Group Research Ltd., and Head-Medical Research at Zeneca Pharmaceuticals.
Dr. Boyd received his undergraduate degree from the University of Birmingham.
Postes actifs de Alan Keith Boyd
Sociétés | Poste | Début |
---|---|---|
Celentyx Ltd.
Celentyx Ltd. BiotechnologyHealth Technology Celentyx Ltd. provides research and development on human immune disease. The firm's services include rapid analysis screening of drug action on physiological and pathological human immune tissues and cells. It provides services by disease, cell type, assay through its ImmuKnowlogy platform technology. The company was founded by Nicholas Mark Barnes and John Gordon in 2004 and is headquartered in Birmingham, the United Kingdom. | Directeur/Membre du Conseil | - |
The Royal College of Physicians | Corporate Officer/Principal | - |
Spark Therapeutics Ireland Ltd.
Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland. | Directeur/Membre du Conseil | 06/09/2011 |
Alan Boyd Consultants Ltd. | Directeur Général | 01/01/2005 |
Transine Therapeutics Ltd.
Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | Directeur/Membre du Conseil | - |
Anciens postes connus de Alan Keith Boyd
Sociétés | Poste | Fin |
---|---|---|
CLINIGEN GROUP PLC | Directeur/Membre du Conseil | 04/04/2022 |
Ark Therapeutics Group Plc
Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | Directeur Technique/Scientifique/R&D | 01/01/2005 |
AstraZeneca Canada, Inc.
AstraZeneca Canada, Inc. Pharmaceuticals: MajorHealth Technology AstraZeneca Canada, Inc. develops and manufactures pharmaceutical drug preparations. Its therapeutic areas include cardiovascular and metabolic disease, oncology, and respiratory, inflammation and autoimmunity. The firm also active in the infection, neuroscience and gastrointestinal disease areas. The company was founded in 1999 and is headquartered in Mississauga, Canada. | Directeur Technique/Scientifique/R&D | - |
Linear Diagnostics Ltd.
Linear Diagnostics Ltd. Medical SpecialtiesHealth Technology Linear Diagnostics Ltd. operates as a diagnostics company based on a novel technology that allows wide range of molecular diagnostics tests to be carried out using a simple optical system. It specializes in molecular diagnostics, novel technology and optical detection. The company was founded by Matt Hicks in 2011 and is headquartered in Birmingham, the United Kingdom. | Directeur/Membre du Conseil | - |
░░░░░░ ░░░░░░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
Formation de Alan Keith Boyd
University of Birmingham | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 10 |
---|---|
Ark Therapeutics Group Plc
Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | Commercial Services |
AstraZeneca Canada, Inc.
AstraZeneca Canada, Inc. Pharmaceuticals: MajorHealth Technology AstraZeneca Canada, Inc. develops and manufactures pharmaceutical drug preparations. Its therapeutic areas include cardiovascular and metabolic disease, oncology, and respiratory, inflammation and autoimmunity. The firm also active in the infection, neuroscience and gastrointestinal disease areas. The company was founded in 1999 and is headquartered in Mississauga, Canada. | Health Technology |
Glaxo Group Research Ltd. | |
Celentyx Ltd.
Celentyx Ltd. BiotechnologyHealth Technology Celentyx Ltd. provides research and development on human immune disease. The firm's services include rapid analysis screening of drug action on physiological and pathological human immune tissues and cells. It provides services by disease, cell type, assay through its ImmuKnowlogy platform technology. The company was founded by Nicholas Mark Barnes and John Gordon in 2004 and is headquartered in Birmingham, the United Kingdom. | Health Technology |
Spark Therapeutics Ireland Ltd.
Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland. | Health Technology |
Zeneca Pharmaceuticals
Zeneca Pharmaceuticals Pharmaceuticals: MajorHealth Technology Zeneca Pharmaceuticals manufactures medicines. | Health Technology |
Alan Boyd Consultants Ltd. | |
Clinigen Ltd.
Clinigen Ltd. Miscellaneous Commercial ServicesCommercial Services Clinigen Ltd. engages in the provision of pharmaceutical products and services. It operates through the following segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires rights to niche hospital-only and critical care products and also provides access to licensed and branded generic. The Unlicensed Medicines segment supplies unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Trial Services offers comparator medicines and services to clinical trials and IITs. The company was founded by Andrew Leaver in June 2010 and is headquartered in Burton-on-Trent, the United Kingdom. | Commercial Services |
Linear Diagnostics Ltd.
Linear Diagnostics Ltd. Medical SpecialtiesHealth Technology Linear Diagnostics Ltd. operates as a diagnostics company based on a novel technology that allows wide range of molecular diagnostics tests to be carried out using a simple optical system. It specializes in molecular diagnostics, novel technology and optical detection. The company was founded by Matt Hicks in 2011 and is headquartered in Birmingham, the United Kingdom. | Health Technology |
Transine Therapeutics Ltd.
Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | Health Technology |